SCHEMBL301107

SCHEMBL301107

CCc1ccc(Cn2ccnc2C)cc1

nearest known ligand 0.71

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.66
L3MBTL1 Q9Y468 1/20 0.66
ALDH1A1 P00352 2/20 0.50
KMT2A Q03164 2/20 0.50
POLB P06746 1/20 0.50
KCNH2 Q12809 5/20 0.46
HTR1A P08908 1/20 0.44
HTR2C P28335 1/20 0.44
MEN1 O00255 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
ALOX12 P18054 1/20 0.41
CYP2C19 P33261 1/20 0.41
JAK2 O60674 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31270697 0.92 LMNA (0.74) LMNAL3MBTL1ALDH1A1KMT2APOLB
SCHEMBL169675 0.87 LMNA (0.68) LMNAL3MBTL1ALDH1A1KMT2APOLB
SCHEMBL31729500 0.87 LMNA (0.68) LMNAL3MBTL1ALDH1A1KMT2APOLB
SCHEMBL2950629 0.85 LMNA (0.71) LMNAL3MBTL1ALDH1A1KMT2APOLB
SCHEMBL11113913 0.84 LMNA (0.64) LMNAL3MBTL1ALDH1A1KMT2APOLB
SCHEMBL277927 0.84 LMNA (0.64) LMNAL3MBTL1ALDH1A1KMT2APOLB
SCHEMBL7807461 0.84 LMNA (0.64) LMNAL3MBTL1ALDH1A1KMT2APOLB
SCHEMBL17102309 0.84 LMNA (0.64) LMNAL3MBTL1ALDH1A1KMT2APOLB
SCHEMBL26789087 0.84 LMNA (0.64) LMNAL3MBTL1ALDH1A1KMT2APOLB
SCHEMBL81625 0.83 LMNA (0.63) LMNAL3MBTL1ALDH1A1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1951684-B1 BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES TARGEGEN INC (US) 2016-07-13 EP disclosed
US-8138199-B2 Use of bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2012-03-20 US disclosed
US-8133900-B2 Use of bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2012-03-13 US disclosed
WO-2012006203-A1 N-CYCLYL-3 - (CYCLYLCARBONYLAMINOMETHYL) BENZAMIDE DERIVATIVES AS RHO KINASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-01-12 WO disclosed
US-20110212077-A1 BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES TARGEGEN, INC. (US) 2011-09-01 US disclosed
WO-2010017122-A2 METHODS OF TREATING THALASSEMIA TARGEGEN INC. (US) 2010-02-11 WO disclosed
US-20090286789-A1 Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases TARGEGEN, INC. (US) 2009-11-19 US disclosed
US-20090275582-A1 Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases IMPACT BIOMEDICINES, INC. 2009-11-05 US disclosed
WO-2007053452-A1 BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES TARGEGEN, INC. (US) 2007-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286789-A1 Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases JAK2, TYK2, LTK LMNA 4525/4885L3MBTL1 3158/4885ALDH1A1 3662/4885
US-20090275582-A1 Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases JAK2, TYK2, JAK3 LMNA 4817/4885L3MBTL1 2347/4885ALDH1A1 3235/4885
US-20110212077-A1 BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES JAK2, TYK2, JAK3 LMNA 4817/4885L3MBTL1 2347/4885ALDH1A1 3235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.